ExagenXGN
Market Cap: $54.6M
About: Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
Employees: 179
Fund manager confidence
Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)
9% more capital invested
Capital invested by funds: $10.6M [Q1] → $11.5M (+$915K) [Q2]
6% more funds holding
Funds holding: 31 [Q1] → 33 (+2) [Q2]
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
2.26% less ownership
Funds ownership: 38.79% [Q1] → 36.53% (-2.26%) [Q2]
Research analyst outlook
We haven’t received any recent analyst ratings for XGN.
Financial journalist opinion
Based on 4 articles about XGN published over the past 30 days